RBC Capital Maintains Axsome Therapeutics (AXSM) Outperform Recommendation with 33.07% Upside Potential

RBC Capital maintains Axsome Therapeutics (AXSM) with an Outperform recommendation, with an average one-year price target of $180.65/share, a 33.07% increase from its latest closing price. The projected annual revenue is 952MM, a 69.58% increase, and the projected annual non-GAAP EPS is -0.07. 670 funds or institutions report positions in AXSM, with an average portfolio weight of 0.36%.